Drug intelligence / Profile preview

INV-141

Development stage: Unknown
Lead developer: InVasc Therapeutics
Modality: Small Molecules

Overview

INV-141 is a clinical-stage pharmaceutical developed by InVasc Therapeutics for treating chronic kidney disease (CKD), particularly in patients with hypertension and diabetes. It is a sister compound to INV-144, which combines an antioxidant (such as alpha-lipoic acid) with losartan, and demonstrated statistical significance in reducing proteinuria in human clinical trials for the same patient population. Limited public data exists on its exact mechanism, active ingredients, or current development status, but it targets renal protection in diabetic nephropathy.

Beyond the preview

Go deeper on INV-141.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INV-141.

Explore the full profile